Blackjack, Biosecurity and Big Bets | Alexander Titus, National Biotech Commissioner
Nucleate PodcastShow Notes
In this episode, we sit down with Alexander Titus—computational biologist, founder of the In Vivo Group, Head of AI at Avidity Biosciences, and commissioner on the National Security Commission on Emerging Biotechnology. From backpacking through Central America on a one-way ticket to becoming the first-ever biotech director at the U.S. Department of Defense, Titus has built a career around a simple ethos: do hard things with good people and have fun along the way.
Titus shares how a last-minute decision to move to the Bay Area, a spontaneous detour to Cuba, and a months-long bike ride from the Arctic Ocean to San Francisco all shaped his appetite for risk, resilience, and unconventional career moves. He talks about living in a Detroit casino while his wife worked night shifts at a children’s hospital—and how using a $100 blackjack bankroll with strict downside protection became both a crash course in probability and an unexpected asset in his grad school interviews.
We dig into his work at the Pentagon, where he helped stand up biotech as a serious national security priority, and his current role on the National Security Commission on Emerging Biotechnology, which recently released a $15 billion roadmap for strengthening the U.S. bioeconomy. Titus explains why he thinks “big initiatives” are really just 1,000 small, well-executed steps, why people and bio-literacy are the most underappreciated pieces of the biotech puzzle, and how policy, industry, and science can—and must—reinforce each other.
Finally, Titus reflects on the real-world promise and hype of AI in biology, from automating tedious knowledge work to accelerating high-throughput experimentation, and why “zero-shot” drug design is still more aspiration than reality. He also gives us a preview of his hard science fiction novel, Synthetic Eden, which forces readers to confront a stark choice: human genetic engineering or human extinction. Throughout the conversation, Titus offers not just stories from a wildly non-linear career, but a playbook for taking smart risks, embracing humility, and building a life at the edge of what’s possible.
More from Nucleate Podcast
The Nucleate Podcast welcomes Matias Serebrinsky, co-founder of Psymed Ventures. Raised in Argentina by a physician father and an economist mother, he shares how his early life influenced his comfort with risk and his drive to do work that helps others. Matias shares his path from Sony marketing to starting CookUnity, and eventually to building a venture fund focused on brain and mental health.
In this episode of the Nucleate Podcast, Dr. Jo Viney, co-founder, president, and CEO of Seismic Therapeutic, shares her trajectory from academic immunology training in London to major biotech companies and startup leadership. She discusses how early clinical lab exposure to autoimmune patients sparked her passion for translational science and highlights why the Boston ecosystem is an ideal place to launch biotech startups due to its unparalleled funding, incubator space, and collaborative peer networks. She also reflects on the lessons learned from co-funding Pandion Therapeutics—including how following surprising data led to a major asset acquisition by Merck—and describes the bittersweet feeling of handing off a company she helped build.
In this episode of the Nucleate Podcast, Joe Betts-LaCroix, co-founder of Retro Biosciences, traces his path from Silicon Valley hardware startups to longevity biotech, explaining that a liquidity event from his first company prompted him to reflect on the limited real-world impact of most tech products compared to medicine, which almost always meaningfully helps people. He describes Retro's approach to navigating biotech regulation through a "daughter test" – asking whether a given regulatory requirement is one he'd genuinely want applied if it were his own family member's treatment on the line. He then explains why the company has set an ambitious but achievable mission of extending healthy human lifespan by 10 years, framing it as a "right-sized" goal for a venture-backed startup.
She started out as a small-town GP in South Africa with zero idea a "biotech industry" even existed. Three decades later, Deborah Dunsire had led the launch of Gleevec — the first targeted cancer therapy ever approved — steered Millennium Pharmaceuticals through an $8.8 billion acquisition, and run two more companies through drug failures, board showdowns, and billion-dollar bets. In this episode, she takes us inside the moments that don't make the press release: a phase one cancer patient still alive today, decades after a drug nobody thought would work; a multiple myeloma patient who happened to be trial patient #007 and was actually named James Bond; and the $60,000 milk-budget cut that nearly tanked employee morale company-wide.
In this episode of the podcast we are joined by Dr. Phillip Sharp, Nobel Prize Laureate and Institute Professor at MIT, who shares his story behind the groundbreaking discovery of RNA splicing. He explains how the work ethic and problem solving instinctions he built early on eventually led him to Caltech, and then MIT, where his 1977 discovery changed how we understand gene expression.